SenegalTuberculosis profile
Population  2014 15 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.1 (2.2–4.1) 21 (15–28)
Mortality (HIV+TB only) 0.43 (0.34–0.52) 2.9 (2.3–3.6)
Prevalence  (includes HIV+TB) 30 (16–49) 205 (107–333)
Incidence  (includes HIV+TB) 20 (18–23) 138 (122–154)
Incidence (HIV+TB only) 1.5 (1.3–1.8) 10 (8.9–12)
         
Case detection, all forms (%) 66 (59–75)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.4 (0–0.8) 16 (9.3–23)
MDR-TB cases among notified pulmonary
TB cases
43 (0–86) 190 (110–280)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 9 278   653
Pulmonary, clinically diagnosed 1 514   234
Extrapulmonary 1 653   0
       
Total new and relapse 13 332    
Previously treated, excluding relapses 315    
Total cases notified 13 647    
Among 9 278 new cases:
206 (2%) cases aged under 15 years; male:female ratio: 2.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 694 (40%) 1 335 (111%) 5 151
Laboratory-confirmed RR-/MDR-TB cases     70
Patients started on MDR-TB treatment ***     49
TB/HIV 2014 Number (%)
TB patients with known HIV status 11 305 (83)
HIV-positive TB patients 831 (7)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 791 (95)
HIV-positive TB patients on antiretroviral therapy (ART) 708 (85)
HIV-positive people screened for TB 10 612  
HIV-positive people provided with IPT 1 332  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (87) 13 180
Previously treated cases, excluding relapse, registered in 2013 (74) 329
HIV-positive TB cases, all types, registered in 2013 (44) 826
RR-/MDR-TB cases started on second-line treatment in 2012 (76) 29
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 7
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 11
% Funded domestically 12%
% Funded internationally 16%
% Unfunded 71%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-30 Data: www.who.int/tb/data